(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -9.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Macrogenics's revenue in 2026 is $157,082,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2026 to be $9,291,657,320, with the lowest MGNX revenue forecast at $3,675,219,772, and the highest MGNX revenue forecast at $14,549,598,855. On average, 8 Wall Street analysts forecast MGNX's revenue for 2027 to be $5,546,581,676, with the lowest MGNX revenue forecast at $373,751,163, and the highest MGNX revenue forecast at $10,371,594,780.
In 2028, MGNX is forecast to generate $9,031,684,147 in revenue, with the lowest revenue forecast at $4,547,305,819 and the highest revenue forecast at $14,562,947,111.